` IMUX (Immunic Inc) vs S&P 500 Comparison - Alpha Spread

IMUX
vs
S&P 500

Over the past 12 months, IMUX has underperformed S&P 500, delivering a return of -34% compared to the S&P 500's +13% growth.

Stocks Performance
IMUX vs S&P 500

Loading
IMUX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
IMUX vs S&P 500

Loading
IMUX
S&P 500
Difference
www.alphaspread.com

Performance By Year
IMUX vs S&P 500

Loading
IMUX
S&P 500
Add Stock

Competitors Performance
Immunic Inc vs Peers

S&P 500
IMUX
ABBV
AMGN
GILD
VRTX
Add Stock

Immunic Inc
Glance View

Market Cap
86.9m USD
Industry
Biotechnology

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 55 full-time employees. The company went IPO on 2014-04-17. The firm is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The firm is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.

IMUX Intrinsic Value
9.183 USD
Undervaluation 90%
Intrinsic Value
Price
Back to Top